4D Molecular Therapeutics reports 2-year PRISM Phase 2b data for wet AMD drug 4D-150
4D Molecular Therapeutics reported two-year data from its PRISM Phase 2b trial of 4D-150 in a broad wet age-related macular degeneration population, with data cutoff May 18, 2026. The company said vision was consistently maintained, retinal thickness was consistently controlled, and treatment burden was reduced by 78% overall and 87% in the recently diagnosed subgroup, with no new inflammation cases after the first 28 weeks.
Key points
- Overall cohort: 78% treatment burden reduction, 2.7 mean supplemental injections per patient vs. 12.0 projected with aflibercept 2 mg Q8W
- Recently diagnosed subgroup (n=15 at 3E10 vg/eye): 87% reduction, 1.6 mean supplemental injections per patient
- Safety: 2.8% (2 of 71) of patients had mild intraocular inflammation within the first 28 weeks; no new cases since
- The 3E10 vg/eye dose was chosen for the 4FRONT Phase 3 trials
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 20, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.